Evaluating new biomarkers for lung health checks

Assessment of Novel Biomarkers in Participants Undergoing Targeted Lung Health Checks

Observational University College, London · NCT05902559

This study is testing new biological markers in people getting lung health checks to see if they can help find serious lung cancers earlier and reduce unnecessary treatments.

Quick facts

Study typeObservational
Enrollment10000 (estimated)
Ages55 Years to 74 Years
SexAll
SponsorUniversity College, London Academic / other
Locations1 site (London)
Trial IDNCT05902559 on ClinicalTrials.gov

What this trial studies

This observational study aims to assess novel biomarkers in participants undergoing targeted lung health checks, particularly focusing on low-dose CT screening for lung cancer. The study seeks to improve the identification of clinically significant lung cancers by integrating biomarker analysis from minimally invasive samples with traditional imaging techniques. By addressing the challenges of distinguishing between benign and malignant nodules, the research hopes to enhance early detection and reduce unnecessary treatments. Participants will be recruited from the NHS Targeted Lung Health Check program.

Who should consider this trial

Good fit: Ideal candidates are adults aged 55 to 74 who have participated in the NHS Targeted Lung Health Check program.

Not a fit: Patients who decline participation or are deemed unfit for enrollment will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved early detection of lung cancer, reducing mortality and unnecessary treatments for patients.

How similar studies have performed: Other studies have shown promise in using biomarkers alongside imaging for lung cancer detection, indicating a potential for success in this approach.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Attended one of more visits as part of the NCL NHS TLHC programme
* Adults aged between 55 years and 74 years and 364 days
* Have capacity and can provide written consent

Exclusion Criteria:

* Declines participation in ALPINE
* Lacking capacity and unable to provide written consent
* Patients who are considered by the clinician to be unfit/not suitable for enrolment in ALPINE

Where this trial is running

London

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Lung Cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.